Affimed N.V. logo
Affimed N.V. AFMD

Quarterly report 2022-Q2
added 08-11-2022

report update icon

Affimed N.V. Financial Ratios 2011-2026 | AFMD

Annual Financial Ratios Affimed N.V.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-8.3 -7.6 -4.5 -8.8 -1.7 -1.6 -4.6 -446.1 - - -

P/S

11.8 11.0 6.8 7.2 25.0 8.3 12.4 34.3 - - -

EPS

- -0.5 -0.5 -0.3 -0.7 -1.0 -0.7 - - - -

EV (Enterprise Value)

478 M 325 M 151 M 183 M 30.9 M 36 M 45.7 M 147 M 106 M 80.3 M -

EBITDA per Share

-0.536 -0.523 -0.49 -0.316 -0.614 -0.954 -0.632 -0.323 - - -

EV/EBITDA

-7.5 -6.6 -2.5 -5.9 -1.0 -1.0 -1.8 -13.0 - - -

PEG

2.08 0.27 0.08 -0.17 -0.06 0.03 0.0 -4.5 - - -

P/B

- 4.3 3.8 4.3 1.6 1.3 1.4 3.6 - - -

P/CF

-5.5 -18.6 -5.6 4.1 -2.3 -1.9 -5.9 -12.6 - - -

ROE %

- -57.46 -83.70 -48.54 -95.71 -83.14 -30.08 -0.82 - - -

ROA %

- -23.54 -28.80 -16.77 -70.03 -66.10 -25.51 -0.62 - - -

ROCE %

- -31.94 -41.95 -24.63 -76.43 -75.63 -30.33 -22.91 - - -

Current Ratio

- 2.2 3.0 3.0 5.6 7.5 8.8 6.6 - - -

DSO

- 31.4 25.3 22.0 200.1 130.4 44.2 97.2 - - -

DIO

- - 69.8 83.2 88.5 69.9 92.3 86.9 - - -

DPO

- - 2518.4 3017.7 1534.9 1890.0 1798.3 1651.2 - - -

Operating Cycle

- - 95.1 105.2 288.6 200.3 136.4 184.1 - - -

Cash Conversion Cycle

- - -2423.3 -2912.4 -1246.3 -1689.7 -1661.9 -1467.1 - - -

All numbers in EUR currency

Quarterly Financial Ratios Affimed N.V.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- - - - - - -0.16 - - - -0.16 - - - -0.17 - - - -0.13 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - - - - - -0.14 - - - -0.14 - - - -0.16 - - - -0.15 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

- - -12.43 -24.86 -24.86 -12.43 -42.64 -60.43 -60.43 -30.22 -61.70 -62.96 -62.96 -31.48 -48.47 -33.97 -33.97 -16.99 -16.99 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

- - -7.56 -15.12 -15.12 -7.56 -19.66 -24.20 -24.20 -12.10 -22.53 -20.86 -20.86 -10.43 -10.43 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

- - -9.51 -19.02 -19.02 -9.51 -25.95 -32.87 -32.87 -16.44 -29.78 -26.69 -26.69 -13.34 -32.66 -38.63 -38.63 -19.32 -19.32 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Multiples are an important financial analysis tool for the company Affimed N.V., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.64 -1.89 % $ 1.09 B canadaCanada
ADMA Biologics ADMA Biologics
ADMA
$ 16.45 0.43 % $ 3.92 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 76.75 0.85 % $ 1.48 B usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 19.93 -1.14 % $ 2.51 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.83 4.23 % $ 4.53 M chinaChina
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.4 -1.81 % $ 1.39 B britainBritain
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 163.82 -0.14 % $ 8.15 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 66.98 3.8 % $ 12.8 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.88 2.51 % $ 908 M israelIsrael
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.75 3.79 % $ 11.7 B usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Cabaletta Bio Cabaletta Bio
CABA
$ 3.41 4.77 % $ 3.98 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 25.71 -0.5 % $ 688 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Codexis Codexis
CDXS
$ 1.1 12.24 % $ 80.7 M usaUSA
Certara Certara
CERT
$ 7.33 1.24 % $ 1.18 B usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA